These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23496666)

  • 21. Adjuvant immunotherapy for non-small cell lung cancer.
    Tucker ZC; Laguna BA; Moon E; Singhal S
    Cancer Treat Rev; 2012 Oct; 38(6):650-61. PubMed ID: 22226940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
    O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
    Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer vaccines: a new therapeutic alternative for lung cancer therapy?
    Raez LE; Santos ES
    Immunotherapy; 2009 Sep; 1(5):727-8. PubMed ID: 20636014
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune-modulating vaccines in non-small cell lung cancer.
    Nemunaitis J; Murray N
    J Thorac Oncol; 2006 Sep; 1(7):756-61. PubMed ID: 17409955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lung cancer vaccine demonstrates enhanced antitumor immunity.
    Oncology (Williston Park); 2001 Jan; 15(1):36, 83. PubMed ID: 11271980
    [No Abstract]   [Full Text] [Related]  

  • 26. The state of the art in non-small cell lung cancer immunotherapy.
    Seetharamu N
    Semin Thorac Cardiovasc Surg; 2014; 26(1):26-35. PubMed ID: 24952755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
    Kakimi K; Nakajima J; Wada H
    Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor vaccine in non-small-cell lung cancer.
    Gonzalez Marinello GM; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):439-45. PubMed ID: 22500681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic vaccines explored in patients with non-small cell lung cancer.
    Ma K; Tang YH
    Anticancer Agents Med Chem; 2014 Feb; 14(2):256-64. PubMed ID: 24237217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
    Sangha R; Butts C
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cell vaccines against non-small cell lung cancer -  an emerging therapeutic alternative.
    Mendoza L
    Klin Onkol; 2014; 27(4):294-8. PubMed ID: 25115721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.
    Talebian Yazdi M; Keene KR; Hiemstra PS; van der Burg SH
    Expert Rev Vaccines; 2014 Jan; 13(1):87-116. PubMed ID: 24308580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.
    Saito K; Nakayama E; Valmori D
    PLoS One; 2016; 11(3):e0150623. PubMed ID: 26937656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Belagenpumatucel-L for the treatment of non-small cell lung cancer.
    Rijavec E; Biello F; Genova C; Barletta G; Maggioni C; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Beltramini S; Grassi MA; Boccardo F; Grossi F
    Expert Opin Biol Ther; 2015; 15(9):1371-9. PubMed ID: 26211534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
    Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
    J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-small-cell lung carcinoma vaccines in clinical trials.
    Rossi A; Maione P; Schettino C; Bareschino MA; Sacco PC; Ambrosio R; Barbato V; Zeppa R; Palazzolo G; Gridelli C
    Expert Rev Vaccines; 2011 Jun; 10(6):887-97. PubMed ID: 21692707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
    Tyagi P; Mirakhur B
    Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Summary of presentations from the 11th targeted therapies for lung cancer meeting: immunotherapy and vaccines for treatment of lung cancer.
    Ujhazy P; Carbone D
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1815-7. PubMed ID: 22005542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.